IFNA1 and hepatocellular carcinoma: We then excluded any cases of de novo HCC occurring within six months after end-of-treatment and obtained an incidence rate of 1.12 per 100py (95%CI: 0.43,1.98) in the DAA group and a higher incidence rate of 3.01 per 100py (95%CI: 0.033, 9.02) in the IFN group, which did not reach statistical significance.